Shares in Puma Biotechnology jumped 40% after the FDA trod lightly around doubts about its filing for approval of breast cancer drug neratinib. But the talking points raised ahead of Wednesday’s ...
(Reuters) -A return to growth in the Americas helped Puma meet first-quarter sales forecasts and its order book for the rest of the year was looking "very good", the German sportswear retailer said on ...
German sportswear brand Puma has recorded a jump in first-quarter profits to EUR109m (US$132m) from EUR36m a year earlier, with CEO Bjorn Gulden upbeat about the year ahead despite ongoing uncertainty ...
With growth in apparel and a positive kickoff of its basketball collection for North America, Puma sees a bright outlook for the rest of the year. In a nutshell: Puma posted strong sales and ...
Simply sign up to the Pharmaceuticals sector myFT Digest -- delivered directly to your inbox. Shares of Puma Biotechnology rose more than 8 per cent in post-market trading on Monday after it received ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results